29 July 2026 is the last day statutory patients in Germany hold a legal entitlement to cannabis flower. From tomorrow, a new framework applies. Three questions in it are still unanswered.
The SHI Contribution Rate Stabilisation Act was published in the Federal Law Gazette on 29 July 2026 (BGBl. 2026 I No. 228). The revised Section 31 (6) of Social Code Book V takes effect on 30 July. Cannabis flower is no longer mentioned in it. It does not drop to secondary status. It is out.
What remains, and on what condition
Three components work together here.
Dried flower is excluded from the entitlement completely. Licensed cannabis-containing finished medicinal products now take priority over pharmacy-compounded preparations. And compounded preparations are blocked from reimbursement for the first six months of any treatment.
So standardised extracts, dronabinol and nabilone stay covered. But as a rule only after a six month trial with a licensed finished product first.
Flower stays prescribable. Just on a private prescription.
There is no explicit transitional provision for ongoing or already approved therapies. Pharmacies report that individual sickness funds have said they will stop dispensing flower prescriptions from 30 July, including where approval was granted earlier. Around 65,000 statutory patients are affected.
For self-payers, nothing changes.
Three questions that now get decided somewhere else
The argument moves to where it belongs: the Federal Joint Committee and the National Association of Statutory Health Insurance Funds. They have to resolve what the legislature left open.
First, protection for existing therapies
Read by wording and purpose, the priority rule looks like it applies to newly initiated treatment, not to therapies that are already running and working. The Act does not say this. And until someone says it with binding effect, every sickness fund decides for itself.
That has to be resolved in favour of patients. Many of them only secured approval after years of appeals and litigation.
Second, off-label use by statute
This one gets too little attention. Systematically it is the worst part.
The waiting period requires a trial with a licensed cannabis-containing finished product. But the available finished products carry narrow indications: spasticity in MS, chemotherapy-induced nausea, chronic back pain. For a large share of the indications where cannabis has actually been prescribed, no suitable licensed product exists.
Which means physicians would have to use a finished product outside its authorisation simply because it contains cannabis, just to unlock reimbursement for a compounded preparation later. Off-label use mandated by law is indefensible under pharmaceutical law and a liability problem for the prescriber. That question needs answering before it gets answered case by case in court.
Third, does any of this save money
Doubtful. And doubtful according to the insurers themselves.
In its statement on the ministerial draft of 19 April 2026, the National Association of Statutory Health Insurance Funds noted that the €130 million savings target was unlikely to be reached, given how many patients would switch to extracts or finished products. The German Hemp Association ran the same numbers and concluded the government had effectively assumed a hundred per cent saving. The realistic risk is higher costs, not lower ones.
For a piece of legislation named after stabilising contribution rates, that is quite something.
The part that hits physicians
One more thing becomes real tomorrow: recourse risk. Once prescribability at the expense of statutory insurance falls away, any remaining reimbursed prescription moves into the scope of prescribing economy audits. Doctors were already cautious here, partly because of clawback exposure. Now they have another reason not to prescribe at all.
That is the quiet multiplier in this reform. It will not show up in any savings calculation, and it will change provision more than the statutory text does.
Some context
Section 31 (6) has been in force since March 2017. It was the starting point of this market and, for over nine years, its longest-standing constant.
Almost everything around it changed. Cannabis moved out of the Narcotics Act into the Medical Cannabis Act. The prior approval requirement was relaxed. Telemedicine and pharmacy mail-order redefined access. Import volumes went from a few hundred kilograms to more than 200 tonnes a year. Reimbursement for flower stayed put through all of it.
That ends today.
I have watched this market since 2019 and I have not seen a single date shift its structure this fundamentally. Reimbursement was never the big lever in volume terms. The private market overtook it a long time ago. What made it matter was something else. It was the last piece of evidence that the legislature treated flower as a normal medicine. That is what goes away today.
The direction being set instead is not subtle. Everything points towards the licensed finished product.
It did not go unchallenged, for the record. Five associations (VCA, ACM, BDCan, BvCW and BPC) opposed the measure in a joint statement, and the German Hemp Association mobilised alongside them. The ACM has since announced a constitutional complaint, which will be brought by Prof. Dr. Oliver Tolmein.
What it means for the industry
From tomorrow the private market is not the exception any more. It is the default. Three things follow.
Price becomes a competitive factor. Where the insurer pays, the prescription decides. Where the patient pays, price decides. And this patient group carries that cost continuously, out of pocket.
Responsibility for care shifts. Pharmacies, telemedicine platforms and suppliers now carry a role the reimbursement system used to share with them. Counselling, treatment continuity, price transparency. All of it.
The clarification phase starts now. No transitional provision, an open off-label question, a constitutional complaint pending. 30 July is not an endpoint. I am curious how this gets resolved and I expect a fair amount of it to end up in the social courts.
If you are building in this market today, build for this framework. Not the one that applied yesterday.
We keep working on it.
